NR4A1 and breast cancer: The Pan-Asian adapted ESMO guidelines recommend a number of options for beyond second-line therapy for patients with mBC, including bevacizumab added to a taxane or capecitabine in those with hormone receptor-positive HER2-negative BC [11].